2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1343

Mortality Due to Sepsis in Patients with Rheumatoid Arthritis
Abstract Number: 60

Mortality of Systemic Lupus Erythematosus in Puerto Rico Assessed By Multiple-Cause-of-Death Analysis
Abstract Number: 2899

Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France
Abstract Number: 1104

Mouse B Cells Require Glucose and Free Fatty Acids As Carbon Sources for Cytokine and Chemokine Secretion
Abstract Number: 465

MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort
Abstract Number: 514

MRI Bone Oedema at Enrollment Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort
Abstract Number: 2030

MRI Changes Associated with Neurological Compromise in Acute Pyogenic Vertebral Osteomyelitis: A Retrospective Study of 121 Patients
Abstract Number: 1306

MRI Erosions in Undifferentiated Arthritis. Different Associations with the Collagen IIA N-Terminal Propeptide (PIIANP) and Galectin-3 in Pre-RA and Other Arthritides
Abstract Number: 1308

MRI Measures of Disease Activity and Joint Damage Are Associated with Patient-Reported Outcomes in Rheumatoid Arthritis
Abstract Number: 1727

MRI Vertebral Corner Inflammation Followed By Fat Deposition Is the Strongest Contributor to the Development of New Bone at the Same Vertebral Corner: A Multi-Level Longitudinal Analysis in Patients with Ankylosing Spondylitis
Abstract Number: 931

mTOR Complex 1 Signaling Is Required for the Steady-State in Vivo Development of Inflammatory Monocytes
Abstract Number: 687

Mucosal Dysregulation in First-Degree Relatives of Ankylosing Spondylitis Patients
Abstract Number: 1374

Mucosal-Associated Invariant T- Cells Are Decreased and Functionally Immature in Peripheral Blood of Patients with Primary Sjögren Syndrome
Abstract Number: 2594

Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy
Abstract Number: 746

Multi-Center Delphi Exercise Reveals Important Key Items in Classifying SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].